Cogent Biosciences, Inc.
COGT
Rangering i aksjer
#3255
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Aksjekurs
$31.37
Sist synkronisert: 2026-10-20
Markedsverdi
$5.44B
Endring (1 dag)
4.54%
Endring (1 år)
97.81%
Land
US
Handel Cogent Biosciences, Inc. (COGT)
Kategori
Healthcare
Antall utestående aksjer for Cogent Biosciences, Inc. (COGT)
Antall utestående aksjer per June 2026: 171.01M
Ifølge Cogent Biosciences, Inc. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 171.01M. Ved slutten av December 2023 hadde selskapet 79.66M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Cogent Biosciences, Inc. (COGT) fra 2015 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 171.01M | 64.66% |
| 2024 | 103.86M | 30.38% |
| 2023 | 79.66M | 35.61% |
| 2022 | 58.74M | 51.66% |
| 2021 | 38.73M | 249.52% |
| 2020 | 11.08M | 45.42% |
| 2019 | 7.62M | 22.43% |
| 2018 | 6.22M | -15.85% |
| 2017 | 7.40M | 26.32% |
| 2016 | 5.86M | 0.00% |
| 2015 | 5.86M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 253.90M | 48.47% |
US
|
|
| 396.00M | 131.57% |
US
|
|
| 478.91M | 180.06% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -63.64% |
NL
|
